EP Patent

EP4456983A1 — Pharmaceutical compositions comprising macitentan as active ingredient and other relevant excipients

Assigned to Adalvo Ltd · Expires 2024-11-06 · 2y expired

What this patent protects

The present invention relates to the preparation of pharmaceutical compositions comprising macitentan is indicated for the treatment of pulmonary arterial hypertension (PAH), having a specific weight ratio of binder to disintegrant in formulation.

USPTO Abstract

The present invention relates to the preparation of pharmaceutical compositions comprising macitentan is indicated for the treatment of pulmonary arterial hypertension (PAH), having a specific weight ratio of binder to disintegrant in formulation.

Drugs covered by this patent

Patent Metadata

Patent number
EP4456983A1
Jurisdiction
EP
Classification
—
Expires
2024-11-06
Drug substance claim
No
Drug product claim
No
Assignee
Adalvo Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.